10/575697

## IAP20 Rec'd PCT/PTO 12 APR 2006

Attorney Docket No.: 10442.204-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Olsen et al.

Confirmation No: TBA

Serial No.: TBA

Group Art Unit: TBA

Filed: April 13, 2006

Examiner: TBA

For: Method for Stable Gene-Amplification in a Bacterial Host Cell

## **INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)**

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: April 13, 2006

Jason J. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212)840-0097



Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.								
Substitute for form 1449A/PTO				Сотр	Complete if Known			
INFORMATION DISCLOSURE				Application Number	(ATBA / 57569/			
				Filing Date	©April 43, 2006			
	STATEMEN	T BY APPLICA	ANT	First Named Inventor	Olsen et al.			
(use as many sheets as necessary)				Art Unit	TBA			
				Examiner Name	TBA			
Sheet	1	of	2	Attorney Docket Number	10442.204-US			

		Ū.	S PATENT DOCU	MENTS	
Examiner Initials	Cite No. 1	Document Number  Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					<del> </del>
			<del></del>		
					<del>.</del>
	1			<u> </u>	
	<del></del>	<del>              </del>			
	-	<del>  -                                    </del>			
	<del>-  </del>				
· · · · · · · · · · · · · · · · · · ·		1			
	-				
<del></del>		·			
		-			
			• •		
		1			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Foreign Patent Document  Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т <sup>6</sup>	
		WO 97/09435	03-13-1997	Therexysys			
		EP 0 972 838	01-19-2001	Roche			
		WO 94/14968	07-07-1994	Novo Nordisk			
		WO 01/90393	11-29-2001	Novozymes			
		WO 02/00907	01-03-2002	Novozymes			
					•		
	l						

Examiner		Date	
Signature	<u>                                      </u>	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.								
Complet	te if Known P 7 5 6 7							
Application Number	LUTBAD/DOY/							
Filing Date	April 13, 2006							
First Named Inventor	Olsen et al.							
Art Unit	TBA							
Examiner Name	TBA							
Attorney Docket Number	10442.204-US							
	Application Number Filing Date First Named Inventor Art Unit Examiner Name							

Examiner's Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
	110.	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		Mollet et al, Journal of Bacteriology, Vol. 175, No. 14 pages 4315-4324 (1993)	
	1		
	1		
			_
	ļ <u> </u>		
	1		
	1		
xaminer Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.